Retatrutide Phase 3 Results: Trial Evidence

Retatrutide phase 3 results are emerging from two large clinical trial programmes, TRIUMPH and TRANSCEND, evaluating this investigational triple receptor agonist in adults with obesity and type 2 diabetes. Retatrutide simultaneously targets the GLP-1, GIP and glucagon receptors, distinguishing it pharmacologically from currently authorised medicines. TRANSCEND-T2D-1 results have been published in The Lancet, while TRIUMPH data have been presented at major scientific congresses. Retatrutide has no marketing authorisation anywhere in the world and is available only within authorised clinical trials. This article summarises what the trial evidence shows, its limitations, and the current UK regulatory position.

What is retatrutide and how does it work?

Retatrutide is an investigational triple agonist acting on GLP-1, GIP and glucagon receptors, influencing appetite, energy expenditure and glucose metabolism. It has no marketing authorisation and is available only within authorised clinical trials.

Retatrutide is an investigational injectable medicine being studied for the treatment of obesity and type 2 diabetes, and it does not currently hold a marketing authorisation anywhere in the world.^[1][9] It belongs to a class of medicines that act on hormone receptors involved in appetite and metabolic regulation. These receptors are expressed in multiple tissues, including the gut, pancreas and brain, rather than exclusively in the gut. Retatrutide is distinctive in that it simultaneously targets three receptors: the glucagon-like peptide-1 (GLP-1) receptor, the glucose-dependent insulinotropic polypeptide (GIP) receptor, and the glucagon receptor. This triple agonist mechanism distinguishes it pharmacologically from currently authorised medicines such as semaglutide (a GLP-1 receptor agonist) and tirzepatide (a dual GIP and GLP-1 receptor agonist).^[2][10]

By activating all three receptors, retatrutide is thought to influence multiple pathways involved in appetite regulation, energy expenditure, insulin secretion and glucose metabolism. The glucagon receptor component is hypothesised, on the basis of preclinical and early-phase human data, to contribute to increased energy expenditure; this is not a feature of currently licensed GLP-1 or dual GIP/GLP-1 medicines.^[13] However, the precise contribution of each receptor to clinical outcomes in humans continues to be evaluated in ongoing trials, and these mechanistic effects should be regarded as under active investigation rather than established fact.

Because retatrutide has no marketing authorisation, it can be prescribed or supplied only within an authorised clinical trial. It is not available through any pharmacy, clinic or online supplier, and any product sold under this name outside a trial setting is not a licensed medicine.

What did the phase 3 clinical trials find?

TRANSCEND-T2D-1, published in The Lancet, showed statistically significant reductions in HbA1c and body weight versus placebo in adults with type 2 diabetes. TRIUMPH programme data have been presented at scientific congresses but peer-reviewed publications are not yet fully available.

The Phase 3 clinical trial programme for retatrutide includes the TRIUMPH programme (TRIUMPH-1 through TRIUMPH-4), which is evaluating retatrutide in adults with obesity, and the TRANSCEND programme, which is evaluating retatrutide in people with type 2 diabetes. TRANSCEND-T2D-1 results have been published in The Lancet and represent the most advanced peer-reviewed evidence currently available for retatrutide in humans.^[8]

In TRANSCEND-T2D-1, retatrutide demonstrated statistically significant reductions in HbA1c and body weight compared with placebo in adults with type 2 diabetes over the trial period.^[8][14] Results from the TRIUMPH programme have been presented at major diabetes and obesity congresses, including the American Diabetes Association (ADA) 2025 and 2026 scientific sessions, though peer-reviewed publications for all TRIUMPH trials are not yet fully available at the time of writing. No marketing authorisation application has yet been granted by any regulatory agency, and no claim can be made about the outcome or timeline of any future regulatory submission.

It is important to understand that these are findings from defined trial populations under controlled conditions, with specific eligibility criteria, monitoring protocols and follow-up periods. Trial participants were excluded if they were pregnant, breastfeeding or planning pregnancy, and contraception requirements applied throughout. The results therefore reflect outcomes in a selected group and cannot be assumed to apply universally. Regulatory agencies, including the MHRA, will assess the totality of the evidence, including safety data, before any authorisation decision is made. No launch date or timeline for UK authorisation can be given.

How reliable are the trial results, and what are their limits?

The TRIUMPH and TRANSCEND trials use randomised, placebo-controlled designs, the most robust available, but results may not apply to all populations and no head-to-head trials against licensed medicines have been published.

The TRIUMPH and TRANSCEND Phase 3 trials are randomised, placebo-controlled studies, which represent the most robust design available for evaluating a new medicine, and their findings carry considerably more weight than the earlier Phase 2 data published in the New England Journal of Medicine in 2023.^[7] Randomisation reduces the risk of selection bias, and placebo control allows the specific effect of the medicine to be separated from non-specific factors such as dietary changes associated with trial participation.

Nevertheless, all clinical trials have inherent limitations that are important to acknowledge. Trial populations are selected according to strict inclusion and exclusion criteria, meaning results may not fully reflect outcomes in the broader population of people with obesity or type 2 diabetes, including those with multiple comorbidities, older adults, or people from ethnic groups that may have been underrepresented. Trial durations, while substantial, may not capture very long-term effects on cardiovascular outcomes, cancer risk or other endpoints that take years to manifest. No head-to-head randomised controlled trials comparing retatrutide directly with currently licensed GLP-1 or GIP/GLP-1 medicines have been published to date.

The comparison of retatrutide's trial results with those of currently licensed medicines such as tirzepatide or semaglutide should be approached with caution. The trials were not conducted head-to-head, and differences in trial design, population characteristics, follow-up duration and outcome definitions make direct numerical comparisons unreliable. Regulatory agencies assess each medicine's benefit-risk profile on its own merits, and the MHRA will do the same if and when a marketing authorisation application is submitted for the UK.

What side effects were reported in the trials?

The most commonly reported side effects are gastrointestinal, including nausea, vomiting, diarrhoea and constipation, typically more frequent during dose escalation. Increases in resting heart rate and cases of pancreatitis have also been reported.

The side effect profile of retatrutide reported in clinical trials is broadly consistent with the class of medicines that act on GLP-1 receptors, though the addition of glucagon receptor agonism introduces some pharmacological differences that are still being characterised. The most commonly reported adverse effects in trials have been gastrointestinal in nature, including nausea, vomiting, diarrhoea and constipation.^[7][3] These effects were generally more frequent at the start of treatment and during dose escalation, and tended to diminish over time.

More serious adverse events observed in the trial programme include:

• Gastrointestinal disorders: Nausea and vomiting were among the most frequent reasons for dose modification or discontinuation in some participants.

• Heart rate changes: Increases in resting heart rate have been noted, consistent with findings seen with other medicines in this class.^[11][7]

• Injection site reactions: Local reactions at the injection site were reported in a proportion of participants.

• Pancreatitis: Cases of pancreatitis have been reported in trials of medicines in this class. The clinical significance in the context of retatrutide continues to be evaluated, and no quantified risk estimate can be given on the basis of currently available data.

Because retatrutide is available only within authorised clinical trials, any adverse events experienced by trial participants must be reported to the trial team under the study protocol. Trial participants are also advised to carry their trial identification card and to inform any healthcare professional, including emergency teams, that they are enrolled in a clinical study, so that appropriate care can be provided. Suspected side effects of medicines taken outside a clinical trial can be reported to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk. Participants who are pregnant, breastfeeding or planning pregnancy are excluded from trials, and appropriate contraception is required throughout participation.

What is retatrutide's current regulatory status in the UK?

Retatrutide has no UK marketing authorisation and no date can be given for when one may be granted. It can only be supplied within an authorised clinical trial; ongoing trials can be found via clinicaltrials.gov or the ISRCTN registry.

Retatrutide does not hold a marketing authorisation in the UK, and no date can be given for when or whether one will be granted.^[1][9] In the UK, medicines are authorised by the Medicines and Healthcare products Regulatory Agency (MHRA), which evaluates the totality of clinical evidence, including safety, efficacy and quality data, before granting a licence. NICE separately assesses whether a medicine should be recommended for NHS use, and local Integrated Care Boards (ICBs) make commissioning decisions. None of these steps has yet occurred for retatrutide.

Because retatrutide is not authorised, it can be prescribed or supplied only within an authorised clinical trial. Participation in such a trial requires meeting specific eligibility criteria, undergoing a formal screening process and consenting to the trial protocol. Information about ongoing trials may be found through official registries such as clinicaltrials.gov (search for retatrutide or the TRIUMPH and TRANSCEND study names) or the ISRCTN registry at isrctn.com. A GP can advise on whether trial participation might be appropriate for an individual.

For people who are currently seeking treatment for obesity or type 2 diabetes, licensed options exist and can be discussed with a GP or specialist. The regulatory pathway for retatrutide remains open, and the MHRA will assess any future marketing authorisation application on its merits. Until authorisation is granted, retatrutide remains an investigational medicine, and no claims about its future availability in the UK can be made.

Is it safe to buy retatrutide online outside of a clinical trial?

It is not legal or safe to purchase retatrutide outside an authorised clinical trial in the UK. Any product sold online under this name is unlicensed and may be falsified, contaminated or incorrectly dosed.

It is not possible to legally purchase retatrutide from any pharmacy, website or supplier in the UK, because the medicine has no marketing authorisation and can only be supplied within an authorised clinical trial. Any product sold online under the name retatrutide is not a licensed medicine and may be a falsified, counterfeit or contaminated substance. Purchasing such products carries serious health risks, including exposure to unknown ingredients, incorrect doses or microbial contamination. Consumers should also be cautious about products advertised through social media or general online marketplaces, which are not regulated supply channels.

The risks of obtaining medicines from unregulated online sources are well established. Falsified medicines may contain no active ingredient, the wrong active ingredient, or harmful contaminants. There is no way for a consumer to verify the contents of a product purchased outside a regulated supply chain. The MHRA actively investigates and takes enforcement action against suppliers of unlicensed medicines. Suspected illegal online medicine sales can be reported to the MHRA at gov.uk/report-problem-medicine-medical-device.

When assessing whether an online pharmacy is legitimate, it is important to check that it is registered with the General Pharmaceutical Council (GPhC) in Great Britain, whose register is publicly searchable at pharmacyregulation.org. In Northern Ireland, the Pharmaceutical Society of Northern Ireland (PSNI) is the relevant pharmacy regulator, and its register is available at psni.org.uk. Online medical services offering consultations should be registered with the Care Quality Commission (CQC) in England (cqc.org.uk), Healthcare Improvement Scotland (his.scot.nhs.uk), Healthcare Inspectorate Wales (HIW) in Wales, or the Regulation and Quality Improvement Authority (RQIA) in Northern Ireland, depending on where the service operates. If you are concerned about a product you have purchased or encountered online, contact your GP or call NHS 111 for advice. For a life-threatening emergency, call 999 or go to your nearest accident and emergency department.

Frequently Asked Questions